Clinical trial
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01226745
Study timeline
Study start (unknown)2010-10-01Date precision: month
Registry last updated2016-07-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
EMD Seronolead sponsor
Merck KGaA, Darmstadt, Germanycollaborator
Ono Pharmaceutical Co., Ltd.collaborator
Mapped research locations
BarcelonaSpain2MoscowRussia2PhiladelphiaPennsylvania, United States1MontrealQuebec, Canada1IndianapolisIndiana, United States1AuroraColorado, United States1DetroitMichigan, United States1RochesterNew York, United States1CharlotteNorth Carolina, United States1WarsawPoland1TucsonArizona, United States1Saint PetersburgRussia1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01226745 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.